Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jun 1, 2026
Reporting period
Not applicable
Filed with the SEC
Jun 4, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-256011
Filed / recorded
Jun 4, 2026, 3:20 AM UTC
Added to OQRO
Oct 6, 2026, 7:14 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
CORCEPT THERAPEUTICS INC
Issuer CIK
1088856
Ticker
CORT
Reporting person
Atabak Mokari
Relationship
Officer
Officer title
Chief Financial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jun 1, 2026
Transaction code
A
Shares / units
634
Price per share
$70.44
Acquired / disposed
Acquired (A)
Shares owned after
15,891
Ownership form
Direct
Amendment
No
Footnotes from the filing
The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Includes 775 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.